Acorda Therapeutics, Inc.
ACORDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001008848
Acorda Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Jun 23, 2023; 17 institutions reported holding it in 13F filings for Q1 2024, worth $2.13M in total; no superinvestor held it.
13F holders, Q2 2024
Institutional positions in Acorda Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
ACOR is no longer listed, and 13F filings after Q1 2024 list far fewer holders. See Q1 2024
- Institutional holders
- 2
- −15 vs. Q1 2024
- Shares held
- 33.7K
- −132.7K (−79.8%) vs. Q1 2024
- Total value
- $8.00K
- −$2.13M (−99.6%) vs. Q1 2024
- New holders
- 0
- 0 more added
- Sold out
- 15
- 0 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACOR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 2 | $8.00K |
| Q1 2024 | 17 | $2.13M |
| Q4 2023 | 15 | $2.33M |
| Q3 2023 | 16 | $2.30M |
| Q2 2023 | 15 | $1.94M |
| Q1 2023 | 30 | $3.71M |
| Q4 2022 | 36 | $4.09M |
| Q3 2022 | 36 | $1.91M |
| Q2 2022 | 35 | $3.08M |
| Q1 2022 | 34 | $5.42M |
| Q4 2021 | 34 | $9.48M |
| Q3 2021 | 36 | $14.7M |
| Q2 2021 | 37 | $18.1M |
| Q1 2021 | 37 | $18.0M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Acorda Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Acadian Asset Management LLC | 33,691 | $8.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Davidson Kempner Capital Management LP | 0 | $0 | 0.00% | −55,145−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −46,761−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −19,260−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −6,107−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −3,736−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −1,137−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −106−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −103−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −51−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| First Manhattan Co | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −14−100.0% | Sold out |